Jim Cramer Says “Organon’s Done” Upon a Caller’s Inquiry

Organon & Co. (NYSE:OGN) was among the stocks on Jim Cramer’s Mad Money radar as he discussed the recent sell-off in AI-related stocks. Mentioning that they own NVO shares, a caller inquired if they should sell them and start a position in OGN, and in response, Cramer said:

No, Organon’s done. Organon’s been, got a takeover bid. Congratulations to them. They got bought by an Indian company, fantastic. I don’t want you to own Novo Nordisk either, though. I think that they are not good at what they do. What I would do if you want to stick in that business is I would go buy some J&J. I think J&J’s been well down from its high, and it’s got a great balance sheet and is doing many, many things right. That’s the one you want.

A woman reading and analyzing stock market data. Photo by Artem Podrez on Pexels

Organon & Co. (NYSE:OGN) develops prescription therapies centered on women’s health, including contraception and fertility products like Nexplanon, NuvaRing, and Follistim AQ, while also selling biosimilars, cholesterol and hypertension drugs, respiratory and allergy treatments, as well as dermatology, bone health, pain management, and other specialty medicines.

While we acknowledge the risk and potential of OGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.